Supplementary Materials

New Napyradiomycin Analogues from *Streptomyces* sp. Strain CA-271078

Daniel Carretero-Molina [1,2], Francisco Javier Ortiz-López [1,*], Jesús Martín [1], Daniel Oves-Costales [1], Caridad Díaz [1], Mercedes de la Cruz [1], Bastien Cautain [1], Francisca Vicente [1], Olga Genilloud [1] and Fernando Reyes [1,*]

[1] Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 34, 18016, Armilla (Granada), Spain; daniel.carretero@medinaandalucia.es (D.C.-M.); jesus.martin@medinaandalucia.es (J.M.); daniel.oves@medinaandalucia.es (D.O.-C.); caridad.diaz@medinaandalucia.es (C.D.); mercedes.delacruz@medinaandalucia.es (M.d.l.C.); bastien.cautain@medinaandalucia.es (B.C.); francisca.vicente@medinaandalucia.es (F.V.); olga.genilloud@medinaandalucia.es (O.G.)

[2] Doctoral Programme in Pharmacy (B15.56.1), Doctoral School in Health Sciences, University of Granada, Spain.

* Correspondence: javier.ortiz@medinaandalucia.es (F.J.O.-L.); fernando.reyes@medinaandalucia.es (F.R.); Tel.: +34-958-993-965 (F.J.O.-L. and F.R.)

Received: 10 December 2019; Accepted: 25 December 2019; Published: date

List of Supplementary Materials:



(**A**)



(**B**)

Figure S1. Electrospray-time of flight (ESI-TOF) (**A**) and UV (**B**) spectra of compound **1**.



Figure S2. ^{1}H NMR (DMSO_d$_6$, 500 MHz) of compound **1**.



Figure S3. ^{13}C NMR (DMSO_d$_6$, 500 MHz) of compound **1**.



Figure S4. COSY of compound **1**.



Figure S5. HSQC spectrum of compound **1**.



Figure S6. HMBC of compound **1**.



Figure S7. ROESY of compound **1**



Figure S8. Energy minimized molecular model of compound **1**.



(**A**)



(**B**)

Figure S9. Electrospray-time of flight (ESI-TOF) (**A**) and UV (**B**) spectra of compound **2**.



Figure S10. ^{1}H NMR (DMSO_d$_6$, 500 MHz) of compound **2**.



Figure S11. ^{13}C NMR (DMSO_d$_6$, 500 MHz) of compound **2**.



Figure S12. COSY of compound **2**.



Figure S13. HSQC spectrum of compound **2**.



Figure S14. HMBC of compound **2.**



Figure S15. NOESY of compound **2**.



Figure S16. ROESY of compound **2**.



Figure S17. Energy minimized molecular model of compound **2**.





(**A**)



(**B**)

Figure S18. Electrospray-time of flight (ESI-TOF) (**A**) and UV (**B**) spectra of compound **3**.



Figure S19. ^{1}H NMR (DMSO_d$_6$, 500 MHz) of compound **3**.



Figure S20. ^{13}C NMR (DMSO_d$_6$, 500 MHz) of compound **3**.



Figure S21. COSY of compound **3**.



Figure S22. HSQC spectrum of compound **3**.



Figure S23. HMBC of compound **3**.



Figure S24. NOESY of compound **3**.



Figure S25. ROESY of compound **3**.



Figure S26. Energy minimized molecular model of compound **3**.



(**A**)



(**B**)

Figure S27. Electrospray-time of flight (ESI-TOF) (**A**) and UV (**B**) spectra of compound **4**.



Figure S28. ^{1}H NMR (DMSO_d$_6$, 500 MHz) of compound **4**.



Figure S29. ^{13}C NMR (DMSO_d$_6$, 500 MHz) of compound **4**.



Figure S30. COSY of compound **4**.



Figure S31. HSQC spectrum of compound **4**.



Figure S32. HMBC of compound **4**.



Figure S33. NOESY of compound **4**.



Figure S34. Energy minimized molecular model of compound **4**.



(**A**)



(**B**)

Figure S35. Electrospray-time of flight (ESI-TOF) (**A**) and UV (**B**) spectra of compound **5**.



Figure S36. ^{1}H NMR (DMSO_d$_6$, 500 MHz) of compound **5**.



Figure S37. ^{13}C NMR (DMSO_d$_6$, 500 MHz) of compound **5**.



Figure S38. COSY of compound **5**.



Figure S39. HSQC spectrum of compound **5**.


HMBC napyradiomycin D1 (5).esp
F2 Chemical Shift (ppm)
F1 Chemical Shift (ppm)

(a)



(b)

Figure S40. (a**)** HMBC of compound **5**. (b) Key HMBC correlation supporting the the etherification of the 18-hydroxy group in **5.**



Figure S41. NOESY of compound **5**.



Figure S42. Overlay of different conformers for compound **5.**



Figure S43. Napyradiomycins metabolites isolated from CA-271078 (**1**-**15**)